LEXICON PHARMACEUTICALS, INC.LXRXEarnings & Financial Report
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 1...
LXRX Q4 FY2025 Key Financial Metrics
Revenue
$5.5M
Gross Profit
$5.3M
Operating Profit
$-14.8M
Net Profit
$-15.5M
Gross Margin
96.3%
Operating Margin
-269.1%
Net Margin
-282.7%
YoY Growth
254.4%
EPS
$-0.04
LEXICON PHARMACEUTICALS, INC. Q4 FY2025 Financial Summary
LEXICON PHARMACEUTICALS, INC. reported revenue of $5.5M (up 254.4% YoY) for Q4 FY2025, with a net profit of $-15.5M (up 54.0% YoY) (-282.7% margin). Cost of goods sold was $201.0K, operating expenses totaled $20.1M.
Key Financial Metrics
| Total Revenue | $5.5M |
|---|---|
| Net Profit | $-15.5M |
| Gross Margin | 96.3% |
| Operating Margin | -269.1% |
| Report Period | Q4 FY2025 |
LEXICON PHARMACEUTICALS, INC. Annual Revenue by Year
LEXICON PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $49.8M).
LEXICON PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
LEXICON PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $5.5M | +254.4% | $-15.5M | -282.7% |
| Q3 FY2025 | $14.2M | +714.6% | $-12.8M | -90.0% |
| Q2 FY2025 | $28.9M | +1685.2% | $3.3M | 11.3% |
| Q1 FY2025 | $1.3M | +15.5% | $-25.3M | -2004.4% |
| Q4 FY2024 | $1.6M | +131.0% | N/A | N/A |
| Q3 FY2024 | $1.7M | +1076.4% | $-64.8M | -3722.6% |
| Q2 FY2024 | $1.6M | +455.7% | $-53.4M | -3304.2% |
| Q1 FY2024 | $1.1M | — | $-48.4M | -4427.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.6M | $1.7M | $1.6M | $1.3M | $28.9M | $14.2M | $5.5M |
| YoY Growth | N/A | 455.7% | 1076.4% | 131.0% | 15.5% | 1685.2% | 714.6% | 254.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $417.2M | $373.4M | $321.1M | $298.4M | $297.7M | $225.6M | $205.9M | $185.0M |
| Liabilities | $128.4M | $133.4M | $142.6M | $152.5M | $174.6M | $96.1M | $85.8M | $77.4M |
| Equity | $288.9M | $240.0M | $178.5M | $145.9M | $123.0M | $129.4M | $120.2M | $107.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-55.1M | $-48.5M | $-53.6M | $-178.8M | $-43.8M | $17.0M | $-23.8M | $-17.2M |